RedHill accelerates research on new drug RHB-107

The South African Health Products Administration (SASAPRA) approved a phase 2/3 study of oral RHB-107 (upamostat) once a day in patients with new coronary pneumonia who have developed symptoms but do not require hospitalization 

The number of American research centers has also increased 

RHB-107 is a new type of antiviral serum protease inhibitor targeting human cytokines, which is expected to be effective against emerging virus variants 

RHB-107 is being developed as a potential treatment to be used as a convenient once-daily oral medicine in the early stage of new coronary pneumonia 

At the same time, in a global Phase 2/3 study of 475 hospitalized patients with severe new coronary pneumonia, RedHill is evaluating its leading oral new coronary pneumonia treatment opaganib, and the top-line results will be announced soon.
 

Tel Aviv, Israel and Raleigh, North Carolina, September 17, 2021/PRNewswire/ - Specialty biopharmaceutical company RedHill Biopharma Ltd.
(NASDAQ: RDHL) (hereinafter referred to as "RedHill" or "Company") It was announced today that after the United States, South Africa has also approved a new drug RHB-107 (upamostat) [1] for the treatment of non-hospitalized patients with symptoms of new coronary pneumonia in a Phase 2/3 study
.

This research has been conducted in the United States, and the number of research centers is expanding to further accelerate patient recruitment

RHB-107 is a new antiviral drug candidate that can target human serine proteases, which are involved in the synthesis of spike proteins to achieve virus entry into target cells
.

RHB-107 targets host cells, so it is also expected to be effective against new virus variants with spike protein mutations

“South Africa continues to face the impact of the new crown pneumonia.
This disease has claimed many lives and caused serious troubles to the medical system
.

South Africa, like the United States and other countries in the world, urgently needs to be able to treat the new crown virus conveniently and effectively both inside and outside the hospital environment.

This phase 2/3 study (NCT04723527) for RHB-107 aims to evaluate its use in the treatment of symptomatic patients with new coronary pneumonia in the early stage of the disease.
It adopts a simple once-a-day oral treatment, which can be used in the largest range of non-hospitalization.
Prescribe and use in the patient group
.

This is a 2-part multicenter, randomized, double-blind, placebo-controlled parallel group study to evaluate the safety and efficacy of RHB-107

At the same time, a phase 2/3 study of opaganib[2] involving 475 patients with severe new coronary pneumonia hospitalized around the world is about to achieve top-line results, which is another advanced oral drug candidate for new coronary pneumonia by RedHill
.

About RHB-107 (upamostat) 

RHB-107 is a proprietary technology, the first of its kind, an oral antiviral agent, which can target human serine protease, which is involved in the synthesis of spike protein to enable the virus to enter the target cell
.

RHB-107 targets human cytokines that are involved in the synthesis of spike proteins to allow the virus to enter target cells, and is therefore expected to be effective against new virus variants with spike protein mutations

About RedHill Biopharma

RedHill Biopharma Ltd.
(NASDAQ: RDHL) is a specialty biopharmaceutical company mainly focusing on gastrointestinal diseases and infectious diseases
.

RedHill promotes the following gastrointestinal drugs: Movantik® for the treatment of adult constipation caused by opioids, Talicia® for the treatment of adult Helicobacter pylori (H.

Note: This press release is a translation of the company's official press release issued in English, and is provided for your convenience
.

For the full English press release, including a disclaimer of forward-looking statements, please visit: https://ir.

1.

2.